LT3442547T - Lactobacillus reuteri mm4-1a, skirta naudoti autizmo spektro sutrikimų gydymui arba prevencijai - Google Patents

Lactobacillus reuteri mm4-1a, skirta naudoti autizmo spektro sutrikimų gydymui arba prevencijai

Info

Publication number
LT3442547T
LT3442547T LTEPPCT/US2017/027827T LTUS2017027827T LT3442547T LT 3442547 T LT3442547 T LT 3442547T LT US2017027827 T LTUS2017027827 T LT US2017027827T LT 3442547 T LT3442547 T LT 3442547T
Authority
LT
Lithuania
Prior art keywords
prevention
treatment
lactobacillus reuteri
autism spectrum
spectrum disorders
Prior art date
Application number
LTEPPCT/US2017/027827T
Other languages
English (en)
Inventor
Mauro Costa-Mattioli
Shelly Alexandra BUFFINGTON
Original Assignee
Baylor College Of Medicine
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Baylor College Of Medicine filed Critical Baylor College Of Medicine
Publication of LT3442547T publication Critical patent/LT3442547T/lt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/742—Spore-forming bacteria, e.g. Bacillus coagulans, Bacillus subtilis, clostridium or Lactobacillus sporogenes
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; PREPARATION THEREOF
    • A23C9/00—Milk preparations; Milk powder or milk powder preparations
    • A23C9/12—Fermented milk preparations; Treatment using microorganisms or enzymes
    • A23C9/123—Fermented milk preparations; Treatment using microorganisms or enzymes using only microorganisms of the genus lactobacteriaceae; Yoghurt
    • A23C9/1234—Fermented milk preparations; Treatment using microorganisms or enzymes using only microorganisms of the genus lactobacteriaceae; Yoghurt characterised by using a Lactobacillus sp. other than Lactobacillus Bulgaricus, including Bificlobacterium sp.
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/02—Suppositories; Bougies; Bases therefor; Ovules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2400/00—Lactic or propionic acid bacteria
    • A23V2400/11—Lactobacillus
    • A23V2400/173—Reuteri
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K2035/11—Medicinal preparations comprising living procariotic cells
    • A61K2035/115—Probiotics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Polymers & Plastics (AREA)
  • Food Science & Technology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Zoology (AREA)
  • Hospice & Palliative Care (AREA)
  • Anesthesiology (AREA)
  • Psychiatry (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
LTEPPCT/US2017/027827T 2016-04-15 2017-04-15 Lactobacillus reuteri mm4-1a, skirta naudoti autizmo spektro sutrikimų gydymui arba prevencijai LT3442547T (lt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662322946P 2016-04-15 2016-04-15
PCT/US2017/027827 WO2017181158A1 (en) 2016-04-15 2017-04-15 Probiotic therapies for developmental disorders and other neurological disorders

Publications (1)

Publication Number Publication Date
LT3442547T true LT3442547T (lt) 2023-09-25

Family

ID=60042831

Family Applications (1)

Application Number Title Priority Date Filing Date
LTEPPCT/US2017/027827T LT3442547T (lt) 2016-04-15 2017-04-15 Lactobacillus reuteri mm4-1a, skirta naudoti autizmo spektro sutrikimų gydymui arba prevencijai

Country Status (14)

Country Link
US (2) US11135252B2 (lt)
EP (2) EP4238573A1 (lt)
DK (1) DK3442547T3 (lt)
ES (1) ES2954147T3 (lt)
FI (1) FI3442547T3 (lt)
HR (1) HRP20231030T1 (lt)
HU (1) HUE062788T2 (lt)
LT (1) LT3442547T (lt)
PL (1) PL3442547T3 (lt)
PT (1) PT3442547T (lt)
RS (1) RS64503B1 (lt)
SI (1) SI3442547T1 (lt)
SM (1) SMT202300283T1 (lt)
WO (1) WO2017181158A1 (lt)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP20231030T1 (hr) * 2016-04-15 2023-12-22 Baylor College Of Medicine Lactobacillus reuteri mm4-1a za upotrebu u liječenju ili prevenciji poremećaja autističnog spektra
KR102463809B1 (ko) * 2019-05-24 2022-11-04 한국식품연구원 클로스트리디오이데스 디피실레에 항균 활성을 갖는 락토바실러스 파라카세이 WiKim0110 균주 및 이를 포함하는 조성물
CN115279194A (zh) * 2020-01-13 2022-11-01 赛欧托生物科技股份有限公司 治疗或改善自闭症和相关病症的方法
CA3205469A1 (en) * 2020-12-18 2022-06-23 The General Hospital Corporation Probiotics compositions and method of using the same to enhance growth and social function in children
CN117320566A (zh) * 2020-12-30 2023-12-29 通用医疗公司 用于治疗自闭症谱系障碍的方法和组合物
CN113180109B (zh) * 2021-04-16 2022-02-18 段云峰 罗伊氏乳杆菌在制备预防或治疗发育障碍类疾病产品中的应用
CN113073066B (zh) 2021-04-16 2022-01-04 段云峰 罗伊氏乳杆菌及其应用、组合物、药物和食品
US12005044B1 (en) 2022-11-29 2024-06-11 Autism Therapeutics Inc. Treatment of autism spectrum disorders with ergothioneine, selenoneine, or combinations thereof
US20240252558A1 (en) * 2023-01-29 2024-08-01 The University Of Chicago Probiotics to rescue maternal immune activation-induced neurodevelopment deficits
JPWO2024242147A1 (lt) * 2023-05-22 2024-11-28

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5413960A (en) 1987-05-01 1995-05-09 Biogaia Ab Antibiotic reuterin
ES2353690T3 (es) 2002-10-03 2011-03-04 Neuropharmacology Services, Llc Oxitocina para su uso en el tratamiento del autismo y del trastorno de asperger.
US7344867B2 (en) 2005-04-15 2008-03-18 Eamonn Connolly Selection and use of lactic acid bacteria for reducing inflammation in mammals
US9084434B2 (en) 2006-09-27 2015-07-21 Little Calumet Holdings Llc Probiotic oral dosage forms
US20100063002A1 (en) 2007-03-13 2010-03-11 Bernd Stahl Method of improving skills with a composition comprising non-digestible saccharide
CN102202527B (zh) * 2008-11-03 2014-12-31 雀巢产品技术援助有限公司 包含益生菌并改善睡眠模式的营养组合物
JP2013507394A (ja) 2009-10-09 2013-03-04 プロセラ インコーポレイテッド 自閉症スペクトル障害と診断されたヒトにおいて自閉症スペクトル障害に関連する少なくとも一つの症状を低減するための、ペディオコッカス属を含む組成物及び方法
MY191538A (en) * 2010-12-31 2022-06-30 Abbott Lab Human milk oligosaccharides to promote growth of beneficial bacteria
EP2609814A1 (en) 2011-12-30 2013-07-03 Nestec S.A. Lactobacillus reuteri DSM 17938 for the development of cognitive function
EP2609813A1 (en) * 2011-12-30 2013-07-03 Nestec S.A. Lactobacillus reuteri DSM 17938 for the development of the enteric nervous system
CA2964480A1 (en) 2014-10-31 2016-05-06 Whole Biome Inc. Methods and compositions relating to microbial treatment and diagnosis of disorders
HRP20231030T1 (hr) * 2016-04-15 2023-12-22 Baylor College Of Medicine Lactobacillus reuteri mm4-1a za upotrebu u liječenju ili prevenciji poremećaja autističnog spektra

Also Published As

Publication number Publication date
SMT202300283T1 (it) 2023-11-13
EP3442547A4 (en) 2019-11-27
EP3442547A1 (en) 2019-02-20
FI3442547T3 (fi) 2023-09-05
EP3442547B1 (en) 2023-06-07
US20210379123A1 (en) 2021-12-09
SI3442547T1 (sl) 2023-11-30
HUE062788T2 (hu) 2023-12-28
DK3442547T3 (da) 2023-09-04
ES2954147T3 (es) 2023-11-20
RS64503B1 (sr) 2023-09-29
HRP20231030T1 (hr) 2023-12-22
PT3442547T (pt) 2023-09-04
WO2017181158A1 (en) 2017-10-19
US11135252B2 (en) 2021-10-05
US20190070226A1 (en) 2019-03-07
EP4238573A1 (en) 2023-09-06
PL3442547T3 (pl) 2023-10-23

Similar Documents

Publication Publication Date Title
IL289650A (en) Azolopyrimidine for the treatment of cancer-related disorders
LT3442547T (lt) Lactobacillus reuteri mm4-1a, skirta naudoti autizmo spektro sutrikimų gydymui arba prevencijai
GB2548873B (en) Use of Cannabidiol in the Treatment of SturgeWeber Syndrome
IL256175A (en) Using exosomes to treat the disease
HRP20210518T1 (hr) Derivati 2,4-tiazolidindiona, namijenjeni liječenju poremećaja središnjeg živčanog sustava
GB2542155B (en) Use of cannabidiol in the treatment of mental disorders
PL3212208T3 (pl) Zastosowanie bakterii l. reuteri do zapobiegania lub leczenia dysbiozy mikrobioty we wczesnych fazach życia
SG10202013034QA (en) Compositions, devices, and methods for the treatment of alcohol use disorder
GB2549278B (en) Use of cannabidivarin in the treatment of autism spectrum disorder
LT3153511T (lt) 2-acilaminotiazolo dariniai, skirti panaudoti šlapimo pūslės/šlapimo takų ligų prevencijai arba gydymui
LT3113778T (lt) Piridazino dariniai, skirti naudoti ataksinio sutrikimo profilaktikai arba gydymui
GB2548930B (en) Heat-inactivated Lactobacillus rhamnosis GMNL-464 for use in the prevention of halitosis
HUE039750T2 (hu) Hidroxi-buspiron mozgászavarok kezelésére
IL274838A (en) Use of MIR101 or MIR128 in the treatment of seizure disorders
PT3197556T (pt) Composição para a prevenção e/ou tratamento de sintomas de alergia
HK1257289A1 (zh) 治疗和/或预防特应性皮炎的il-17c拮抗剂
ITUA20163037A1 (it) Formulazioni per uso nel trattamento o prevenzione di disturbi urologici
IL263468A (en) New molecules to treat inflammation
GB201411916D0 (en) Stretcher bar system, retro-fit kit and method of application of the retro-fit kit